Project Grant R44CA291345
Award Date
9/6/24
Completion Date
8/31/26
Dollars Obligated
$1.6M
Federal Agency
National Cancer Institute
Awardee
Shasqi Inc. (ZDH5UZ2858G3)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94107, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $644,034 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a nanoparticle-based drug delivery platform that uses radiation therapy to trigger the localized release of chemotherapy within tumor tissue. The goal is to improve the therapeutic window of chemoradiation treatment by enhancing tumor control while mitigating systemic toxicities....
This federal Project Grant award for $716,314.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma (GEA). The key products and services to be delivered include: Utilizing novel immune-competent mouse models of FGFR2-altered GEA to develop and test highly efficacious FGFR2 biparatopic antibodies (BIPABs) and FGFR2-targeted antibody-drug conjugates (ADCs), alone or in...
This Project Grant award of $399,444.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cancure LLC, a woman-owned small business, aims to screen a panel of fusion proteins composed of a peptide and a binding agent. The goal is to identify the best candidate to advance or make a go/no-go decision regarding the fusion product, while also conducting pilot de-risking biochemical/biophysical characterizations. This research seeks to develop a novel agent...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $863,708 to Mirecule, Inc. to develop an antibody-oligonucleotide conjugate therapy for treating head and neck squamous cell carcinoma. The award period runs from September 18, 2024 to August 31, 2026. The key products or services to be delivered under this award include: 1) validating the efficacy of the MC-30 antibody-RNA conjugate in preclinical cancer models, 2) executing...
The National Cancer Institute (NCI) awarded a $406,258 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Georgia State University Research Foundation Inc. on July 15, 2025. The grant supports research to develop novel covalent anti-cancer drugs using phosphorus fluoride exchange (PFEX) click chemistry. The key objectives are to: 1) synthesize PFEX warheads with different substituents to optimize stability and reactivity, 2) compare PFEX warheads to α,β-unsaturated carbonyl warheads,...
This Project Grant award of $676,567.00 was provided by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), to The Regents of the University of California, San Francisco (UCSF). The award will fund a multi-year research project to systematically test a transforming growth factor beta (TGFB) targeted theranostic radiopharmaceutical therapy approach across preclinical cancer models. The research aims to assess the biological effectiveness of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,500.00 to Chapman University to develop and evaluate peptide-doxorubicin conjugates for mitigating cardiotoxicity and overcoming drug resistance in cancer. The key objectives are to investigate the mechanisms by which these peptide-drug conjugates can selectively target and kill drug-resistant cancer cells while reducing adverse cardiotoxic effects, and to conduct in vivo...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding of $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel inhibitors of the NSMASE2 enzyme for enhancing the effectiveness of immune checkpoint inhibitors in cancer treatment. The project aims to synthesize and test PDDC analogs to improve the potency, solubility, and pharmacokinetics of NSMASE2 inhibitors. Promising...
The University of California, Davis was awarded a $615,399 Project Grant by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to develop a transformable nanoparticle (TNP) platform capable of transforming into nanofibrillar networks that can effectively deliver immunomodulatory peptides, small molecules, and proteins to the tumor microenvironment. This 5-year research project aims to optimize the TNP/TCTS therapeutic platform for on-demand modulation of the tumor...